Table 6 Rho Assessment of relationships between menstrual characteristics and the most common symptoms in the Post-acute Phase—A Comprehensive Study of reported changes in menstruation, period, volume, and dysmenorrhea [n(%)]
Symptom | Group A, n = 442 | Group Bb, n = 427 | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
Menstruation | Period | Volume | Dysmenorrheaa | ||||||
Delayed | Advanced | Prolonged | Shortened | Increased | Decreased | Worsen | |||
Fatigue | 118(21.5) | 27(4.9) | 41(7.5) | 14(2.6) | 62(11.3) | 80(14.6) | 49(8.9)a | 246(44.8)b | 549 |
Rho | 0.060 | 0.027 | -0.012 | -0.050 | 0.078* | 0.02 | 0.085* | 0.113** | |
Rho 95%CI | -0.006 to 0.128 | -0.038 to 0.087 | -0.083 to 0.053 | -0.123 to 0.022 | 0.013 to 0.134 | -0.043 to 0.087 | 0.023 to 0.141 | 0.044 to 0.18 | |
P | 0.078 | 0.423 | 0.727 | 0.142 | 0.022 | 0.554 | 0.013 | 0.001 | |
Cough | 93(19.7) | 22(4.7) | 32(6.8) | 14(3) | 46(9.8) | 67(14.2) | 39(8.3) | 228(48.4) | 471 |
Rho | 0.002 | 0.01 | -0.037 | -0.015 | 0.008 | 0.006 | 0.043 | 0.016 | |
Rho 95%CI | -0.066 to 0.07 | -0.058 to 0.077 | -0.106 to 0.033 | -0.083 to 0.053 | -0.059 to 0.073 | -0.068 to 0.074 | -0.019 to 0.105 | -0.049 to 0.086 | |
P | 0.957 | 0.777 | 0.271 | 0.651 | 0.815 | 0.864 | 0.203 | 0.64 | |
Body weakness | 74(21.0) | 17(4.8) | 21(5.9) | 10(2.8) | 40(11.3) | 51(14.4) | 34(9.6)a | 159(45)b | 353 |
Rho | 0.027 | 0.013 | -0.055 | -0.018 | 0.05 | 0.01 | -0.076* | 0.068* | |
Rho 95%CI | -0.037 to 0.094 | -0.056 to 0.078 | -0.122 to 0.011 | -0.082 to 0.048 | -0.018 to 0.119 | -0.056 to 0.077 | -0.142 to -0.008 | 0.001 to 0.132 | |
P | 0.431 | 0.7 | 0.108 | 0.591 | 0.14 | 0.775 | 0.025 | 0.046 | |
Phlegm | 69(21.9) | 13(4.1) | 21(6.7) | 9(2.9) | 34(10.8) | 39(12.4) | 28(8.9) | 158(50.2) | 315 |
Rho | 0.042 | -0.013 | -0.029 | -0.016 | 0.032 | -0.036 | 0.048 | -0.015 | |
Rho 95%CI | -0.022 to 0.109 | -0.076 to 0.053 | -0.095 to 0.034 | -0.08 to 0.053 | -0.034 to 0.1 | -0.1 to 0.033 | -0.019 to 0.125 | -0.077 to 0.05 | |
P | 0.214 | 0.699 | 0.385 | 0.646 | 0.348 | 0.289 | 0.16 | 0.65 | |
Memory decline | 61(22.6) | 14(5.2) | 21(7.8) | 7(2.6) | 35(13.0) | 45(16.7) | 33(12.2)a | 103(38.1)b | 270 |
Rho | 0.049 | 0.023 | 0.002 | -0.024 | 0.078* | 0.051 | 0.129** | 0.148** | |
Rho 95%CI | -0.015 to 0.113 | -0.045 to 0.085 | -0.061 to 0.066 | -0.087 to 0.041 | 0.004 to 0.148 | -0.017 to 0.121 | 0.056 to 0.199 | 0.079 to 0.21 | |
P | 0.147 | 0.506 | 0.96 | 0.481 | 0.022 | 0.135 | <0.001 | <0.001 | |
Insomnia | 49(22.3) | 7(3.2) | 13(5.9) | 7(3.2) | 20(9.1) | 38(17.3) | 23(10.5)a | 92(41.8)b | 220 |
Rho | 0.038 | -0.037 | -0.039 | -0.001 | -0.009 | 0.054 | 0.072* | 0.085* | |
Rho 95%CI | -0.023 to 0.105 | -0.093 to 0.03 | -0.1 to 0.019 | -0.064 to 0.072 | -0.073 to 0.062 | -0.015 to 0.118 | 0.003 to 0.144 | 0.019 to 0.151 | |
P | 0.263 | 0.279 | 0.247 | 0.969 | 0.788 | 0.11 | 0.034 | 0.012 | |